Found: 216
Select item for more details and to access through your institution.
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 11, p. e369, doi. 10.1016/j.clml.2023.08.001
- By:
- Publication type:
- Article
Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 17, p. 17981, doi. 10.1002/cam4.6439
- By:
- Publication type:
- Article
Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers.
- Published in:
- Cancers, 2023, v. 15, n. 12, p. 3214, doi. 10.3390/cancers15123214
- By:
- Publication type:
- Article
Eine klinische Perspektive auf die Behandlung von chronischer myeloischer Leukämie in der chronischen Phase.
- Published in:
- Kompass Onkologie, 2023, v. 10, n. 1, p. 2, doi. 10.1159/000529704
- By:
- Publication type:
- Article
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia.
- Published in:
- Therapeutic Advances in Hematology, 2023, v. 14, p. 1, doi. 10.1177/20406207231154708
- By:
- Publication type:
- Article
Social needs and health-related quality of life among hematologic cancer survivors.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 11, p. 8919, doi. 10.1007/s00520-022-07281-2
- By:
- Publication type:
- Article
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01361-w
- By:
- Publication type:
- Article
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01309-0
- By:
- Publication type:
- Article
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 6, p. 838, doi. 10.1007/s12185-022-03314-y
- By:
- Publication type:
- Article
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 3, p. 378, doi. 10.1111/bjh.17689
- By:
- Publication type:
- Article
How the Study of Leukemias Inspired a Decades-Long Career.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 11, p. 706
- By:
- Publication type:
- Article
Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01274-X
- By:
- Publication type:
- Article
Poster: CML-081: Effect of Comorbidities on Response Outcomes With First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01406-3
- By:
- Publication type:
- Article
Poster: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01408-7
- By:
- Publication type:
- Article
Poster: CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01409-9
- By:
- Publication type:
- Article
Poster: CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01411-7
- By:
- Publication type:
- Article
CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S326, doi. 10.1016/S2152-2650(21)01766-3
- By:
- Publication type:
- Article
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S328, doi. 10.1016/S2152-2650(21)01769-9
- By:
- Publication type:
- Article
CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S334, doi. 10.1016/S2152-2650(21)01781-X
- By:
- Publication type:
- Article
CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S335, doi. 10.1016/S2152-2650(21)01784-5
- By:
- Publication type:
- Article
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinib.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2641, doi. 10.1002/cncr.33539
- By:
- Publication type:
- Article
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01119-w
- By:
- Publication type:
- Article
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01106-1
- By:
- Publication type:
- Article
Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 11, p. 1894, doi. 10.1002/cncr.33409
- By:
- Publication type:
- Article
Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health "All of Us" Research Program.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 11, p. 3646, doi. 10.1002/cam4.3924
- By:
- Publication type:
- Article
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 6, p. 808, doi. 10.1111/ejh.13608
- By:
- Publication type:
- Article
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. 493, doi. 10.1002/ajh.26079
- By:
- Publication type:
- Article
Knowledge of prostate cancer among African American men: A systematic review.
- Published in:
- Prostate, 2021, v. 81, n. 3, p. 202, doi. 10.1002/pros.24097
- By:
- Publication type:
- Article
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
- Published in:
- Hematological Oncology, 2020, v. 38, n. 5, p. 654, doi. 10.1002/hon.2771
- By:
- Publication type:
- Article
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
- Published in:
- Acta Haematologica, 2020, v. 143, n. 6, p. 567, doi. 10.1159/000506346
- By:
- Publication type:
- Article
Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1296, doi. 10.1002/ajh.25943
- By:
- Publication type:
- Article
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00975-2
- By:
- Publication type:
- Article
The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. 1127, doi. 10.1002/ajh.25907
- By:
- Publication type:
- Article
A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
- Published in:
- 2020
- By:
- Publication type:
- journal article
An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 4, p. 451, doi. 10.1007/s00280-020-04132-x
- By:
- Publication type:
- Article
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00929-8
- By:
- Publication type:
- Article
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 612, doi. 10.1002/ajh.25769
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0316-3
- By:
- Publication type:
- Article
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Long-term results of frontline dasatinib in chronic myeloid leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. 1388, doi. 10.1002/ajh.25648
- By:
- Publication type:
- Article
Treatment-Free Remission in Chronic Myeloid Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 12, p. 686
- By:
- Publication type:
- Article
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
2211. Impact of Early Fiberoptic Bronchoscopy on Microbiological Diagnostic Rate and Clinical Outcomes of Pneumonia in Acute Leukemia Patients.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S753, doi. 10.1093/ofid/ofz360.1889
- By:
- Publication type:
- Article
Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 10, p. E256, doi. 10.1002/ajh.25571
- By:
- Publication type:
- Article
Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S206, doi. 10.1016/j.clml.2019.07.068
- By:
- Publication type:
- Article
Pooled Clinical Safety Analysis of CPX-351 Versus Conventional Chemotherapy in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S214, doi. 10.1016/j.clml.2019.07.084
- By:
- Publication type:
- Article